The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh, North Carolina, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye diseases. With irreversible vision loss progressing rapidly in many conditions, gene therapy continues to emerge as a critical one-time intervention that can preserve and restore sight for patients in need.
Attendees will gain access to exclusive data and insights, including preclinical updates from Opus Genetics, Coave Therapeutics, and Axovia Therapeutics, alongside pivotal 2025 clinical progress shared by Ocugen, Adverum Biotechnologies, and Beacon Therapeutics. A major highlight is the Interview the Investor session with James Kasuboski, Partner & Head of Research at Luma Group, where attendees will hear directly from investors on the criteria shaping ophthalmic gene therapy funding and strategies for building sustainable development approaches.
Additional sessions will spotlight patient-led regulatory engagement, comparative analyses of delivery approaches, and strategies for optimizing trial design and patient retention. With a carefully balanced agenda – equally split between preclinical and clinical content – this meeting provides a comprehensive view of the ophthalmic gene therapy pipeline.
Featuring 18+ senior expert speakers, 3+ hours of clinical data, 2+ hours of preclinical research, and 6+ hours of networking opportunities, the summit unites biopharma leaders, investors, and innovators to accelerate progress from IND through to late-stage clinical development.
Join us in Raleigh to connect with decision-makers across the ophthalmic gene therapy value chain, uncover the next wave of breakthroughs beyond Luxturna, and ensure your therapy reaches patients faster.
View the full event program on our website here: https://ter.li/0duhtz